Enrico Martin

66 Chapter 3 15. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus s tandard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol . 2017;18(6):812-822. doi:10.1016/S1470-2045(17)30334-0 16. Higham CS, Steinberg SM, Dombi E, et al. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma . 2017;2017:8685638. doi:10.1155/2017/8685638 17. Casparie M, Tiebosch ATMG, Burger G, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol . 2007;29(1):19-24. 18. Hothorn T, Hornik K, Zeileis A. Unbiased Recursive Partitioning: A Conditional Inference Framework. J Comput Graph Stat . 2006;15(3):651-674. 19. Therneau TM, Crowson CS, Elizabeth AJ. Adjusted Survival Curves. cran.r-project. org/web/packages/sur vival/vignet tes/ adjcurve.pdf . 20. Kolberg M, Holand M, Agesen TH, et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro Oncol . 2013;15(2):135-147. doi:10.1093/neuonc/ nos287 21. Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma . 2009;2009:756395. doi:10.1155/2009/756395 22. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol . 2005;23(33):8422-8430. doi:10.1200/ JCO.2005.01.4886 23. Hagel C, Zils U, Peiper M, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral ner ve sheath tumors. J Neurooncol . 2007;82(2):187-192. doi:10.1007/s11060-006-9266-2 24. Martin E, Muskens IS, Coert JH, Smith TR, Broekman MLD. Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis. Neuro- Oncology Pract . 2018:1-10. 25. LaFemina J, Qin L-X, Moraco NH, et al. Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors. Ann Surg Oncol . 2013;20(1):66-72. doi:10.1245/s10434-012- 2573-2 26. Watson KL, Al Sannaa GA, Kivlin CM, et al. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg . 2017;126(1):319-329. doi:10.3171/2015.12.JNS152443 27. Schaefer I-M, Fletcher CDM. Malignant peripheral nerve sheath tumor (MPNST) arising in diffuse-type neurofibroma: clinicopathologic characterization in a series of 9 cases. Am J Surg Pathol . 2015;39(9):1234-1241. doi:10.1097/ PAS.0000000000000447 28. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys . 1998;42(2):351-360. 29. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol Off J Eur Soc Med Oncol . 2011;22(1):207-214. doi:10.1093/annonc/mdq338